Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer

To evaluate the tolerability and safety of SHR-8068 in combination with adebrelimab in subjects with advanced NSCLC To evaluate the efficacy of SHR-8068 in combination with adebrelimab and platinum-based chemotherapy in subjects with advanced NSCLC

Trial Details

NCT ID
NCT05416775
Phase
PHASE1 / PHASE2
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SHR-8068；Adebrelimab
  • SHR-8068；adebrelimab and platinum-based chemotherapy
  • Adebrelimab；platinum-based chemotherapy
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Hefei, Anhui, China|31.86389,117.28083
  • Chengdu, Chengdu, China|30.66667,104.06667
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Nanning, Guangxi, China|22.81667,108.31667

Key Eligibility Criteria

  • Age 18\~75 years old, both male and female
  • Stage 1: pathologically diagnosed, incurable NSCLC subjects who have failed standard treatment
  • Stage 2: have a histologically or cytologically confirmed diagnosis of relapsed or metastatic NSCLC; have not received prior systemic treatment for…
  • At least one measurable lesion based on RECIST v1.1 criteria

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →